Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Vaccines and Immunnotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Department of Physiology, Neuroscience Unit, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Pre-Clinical Research Unit, King Fahad Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Travel Med Infect Dis. 2020 May-Jun;35:101735. doi: 10.1016/j.tmaid.2020.101735. Epub 2020 May 6.
The rapidly spreading Coronavirus Disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), represents an unprecedented serious challenge to the global public health community. The extremely rapid international spread of the disease with significant morbidity and mortality made finding possible therapeutic interventions a global priority. While approved specific antiviral drugs against SARS-CoV-2 are still lacking, a large number of existing drugs are being explored as a possible treatment for COVID-19 infected patients. Recent publications have re-examined the use of Chloroquine (CQ) and/or Hydroxychloroquine (HCQ) as a potential therapeutic option for these patients. In an attempt to explore the evidence that supports their use in COVID-19 patients, we comprehensively reviewed the previous studies which used CQ or HCQ as an antiviral treatment. Both CQ and HCQ demonstrated promising in vitro results, however, such data have not yet been translated into meaningful in vivo studies. While few clinical trials have suggested some beneficial effects of CQ and HCQ in COVID-19 patients, most of the reported data are still preliminary. Given the current uncertainty, it is worth being mindful of the potential risks and strictly rationalise the use of these drugs in COVID-19 patients until further high quality randomized clinical trials are available to clarify their role in the treatment or prevention of COVID-19.
由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起的迅速传播的冠状病毒病（COVID-19）大流行，对全球公共卫生界构成了前所未有的严重挑战。该疾病在国际上迅速传播，发病率和死亡率都很高，因此寻找可能的治疗干预措施成为全球的当务之急。虽然针对 SARS-CoV-2 的批准特定抗病毒药物仍然缺乏，但大量现有的药物正被探索作为 COVID-19 感染患者的可能治疗方法。最近的出版物重新审查了氯喹（CQ）和/或羟氯喹（HCQ）作为这些患者潜在治疗选择的用途。为了探索支持其在 COVID-19 患者中使用的证据，我们全面审查了以前使用 CQ 或 HCQ 作为抗病毒治疗的研究。CQ 和 HCQ 均在体外显示出有希望的结果，但这些数据尚未转化为有意义的体内研究。虽然少数临床试验表明 CQ 和 HCQ 对 COVID-19 患者有一些有益的影响，但大多数报告的数据仍然是初步的。鉴于目前的不确定性，值得注意的是这些药物在 COVID-19 患者中的潜在风险，并在进一步提供高质量的随机临床试验以明确其在 COVID-19 治疗或预防中的作用之前，严格合理使用这些药物。
